Results 201 to 210 of about 788,644 (353)
Humans are not unique: difficult birth is common in placental mammals
ABSTRACT Human childbirth is widely presumed to be uniquely difficult and dangerous compared to birth in other mammals. Tight fetopelvic proportions can result in obstructed labour and contribute to high rates of maternal and neonatal mortality. Ideas summarised under the ‘obstetrical dilemma’ have contributed to this assumption by explaining difficult
Nicole D. S. Grunstra
wiley +1 more source
COVID-19 as a natural experiment intervention to reduce new HIV infections among Australian MSM. [PDF]
Nghiem VTH, Braithwaite RS.
europepmc +1 more source
Abstract Background Autogenous grafts remain the gold standard for soft tissue augmentation, but allogeneic dermal matrices (ADMs) offer a viable alternative. Limited cellular infiltration and neovascularization restrict ADM efficacy; this study investigates a novel microsurfaced ADM (MS‐ADM) designed to address these limitations. Methods This 180‐day,
Michael K. McGuire +4 more
wiley +1 more source
Blood demand and utilization among pregnant and postpartum women with and without HIV infections at the university teaching Hospital, Zambia. [PDF]
Kanagasabai U +7 more
europepmc +1 more source
Initial productive and latent HIV infections originate in vivo by infection of resting T cells. [PDF]
Wietgrefe SW +31 more
europepmc +1 more source
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik +3 more
wiley +1 more source
Case study of PEPFAR funding cuts on HIV infections and deaths: reversing hard-won gains. [PDF]
Apollo T +13 more
europepmc +1 more source
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld +9 more
wiley +1 more source

